Search by Title Article Topic - Any -AdvocacyCertificationClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHFSA Annual Scientific MeetingHFSA AwardsHFSA Board Certification ReviewHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterHFSA MembershipIn The NewsIndustryJournal of Cardiac FailureMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Nov 16 2021 | US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction Industry News Industry Read More Oct 15 2021 | AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial Industry News Industry Read More Aug 27 2021 | AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19 Industry News Industry Read More Aug 27 2021 | Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction Industry News Industry Read More Aug 19 2021 | US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction Industry News Industry Read More Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Nov 16 2021 | US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction Industry News Industry Read More
Oct 15 2021 | AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial Industry News Industry Read More
Aug 27 2021 | AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19 Industry News Industry Read More
Aug 27 2021 | Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction Industry News Industry Read More
Aug 19 2021 | US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction Industry News Industry Read More
